Navigation Links
Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
Date:9/16/2009

HEIDELBERG, Germany, September 16 /PRNewswire/ --

- Integrated Chemical Genetics and Proteomics Approach Identifies new Potential Drug Targets in Wnt Pathway

Cellzome announces today, the publication entitled "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling"** is now available online in Nature.

The paper describes how Cellzome's quantitative chemical proteomics platform was used to identify a small molecule which plays a critical role in the regulation of the Wnt pathway. The small molecule stabilizes axin by inhibiting the poly-ADP-ribosylating enzymes tankyrase 1 and tankyrase 2. Both tankyrase isoforms interact with a highly conserved domain of axin and stimulate its degradation through the ubiquitin-proteasome pathway. Thus, the study provides new mechanistic insights into the regulation of axin protein homeostasis and presents new avenues for therapeutic intervention in this key cancer pathway. This transforming science was conducted as part of the collaboration between Cellzome and Novartis Institutes for Biomedical Research (NIBR).

Dr. David Simmons, CSO of Cellzome, said: "This paper shows the powerful insights provided by Cellzome's proprietary chemical proteomics technology platform. Our platform also includes Kinobeads(TM) which we use for the discovery and development of a new generation of kinase inhibitors and Episphere(TM) for the discovery of novel drug candidates for epigenetic targets."

** Huang, S., et.al. "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling", Nature, 10.1038/nature08356, 2009.

About Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for the screening and profiling of kinase inhibitors in physiologically-relevant cells and tissues. The most advanced program, targeting PI3K(gamma), is anticipated to enter the clinic in 2010, and several other programs are in early preclinical testing.

Cellzome is expanding its distinctive technology, in a novel form called Episphere(TM), to the discovery and development of novel drug candidates for epigenetic targets in their protein complexes.

Cellzome has significant collaborations with GSK and Johnson & Johnson. Its holding company is domiciled in the US and it employs about 90 people at its two laboratories in Cambridge, UK and Heidelberg, Germany.


'/>"/>
SOURCE Cellzome Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline and Cellzome Announce Major Strategic Alliance
2. Abbott Wins Top Honor in Wall Street Journal Technology Innovation Awards
3. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
4. China Agro-Technology Holdings Announces Launch of Agricultural Biotech Website
5. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
6. Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Tata Interactive Systems Initiates Vertical-Focused Learning Solutions for Health Care, Pharmaceutical, and Biotechnology
11. Hyland Software Provides Grant Assistance to Kick-Start Technology Projects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... of cannabis testing technology at the Spring 2016 Marijuana Business Conference and Expo. ... pesticides, residual solvents, heavy metals, and more. Expo attendees can stop by booth ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... mobile devices with fingerprint recognition for secure access, voice recognition for hands-free communication, ... ways consumers are interacting with biometrics technology today. But if they asked ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... Clark has joined the company as an Expert Consultant. Mr. Clark was ... collaborations and managing the development of small molecule monographs based on analytical methods. ...
Breaking Biology Technology:
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
Breaking Biology News(10 mins):